Physician profile
Michael Lane
NPI 1073007159
$1,636.25
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.69 · 2020: $77.84 · 2021: $373 · 2022: $425 · 2023: $692 · 2024: $34.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.35 | 2021-2023 | Emgality, Jardiance, Mounjaro |
| Novo Nordisk INC | $178.78 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $177.51 | 2022-2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $145.29 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $134.05 | 2021-2022 | |
| Pfizer INC. | $109.07 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $85.28 | 2021-2024 | |
| Abbvie INC. | $63.41 | 2023 | |
| Dexcom, INC. | $60.53 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $58.60 | 2021-2023 | Myrbetriq, Veozah |
| Axsome Therapeutics, INC. | $57.79 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $56.51 | 2020-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $37.06 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.53 | 2022-2023 | Jardiance |
| Nevro Corp. | $29.86 | 2023 | Senza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.67 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.13 | 2022 | |
| Sanofi Pasteur INC. | $21.84 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.41 | 2019 | |
| Halozyme INC | $19.35 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.83 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.82 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.52 | 2023 | Xifaxan |
| Abbott Laboratories | $15.70 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $14.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.